Elevated luteinizing hormone despite normal testosterone levels in older men—natural history, risk factors and clinical features

DOI:
10.1111/cen.13524

Document Version
Accepted author manuscript

Link to publication record in Manchester Research Explorer

Citation for published version (APA):

Published in:
Clinical Endocrinology

Citing this paper
Please note that where the full-text provided on Manchester Research Explorer is the Author Accepted Manuscript or Proof version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version.

General rights
Copyright and moral rights for the publications made accessible in the Research Explorer are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Takedown policy
If you believe that this document breaches copyright please refer to the University of Manchester’s Takedown Procedures [http://man.ac.uk/04Y6Bo] or contact uml.scholarlycommunications@manchester.ac.uk providing relevant details, so we can investigate your claim.
Elevated Luteinising Hormone despite Normal Testosterone Levels in older Men
– Natural History, Risk Factors, and Clinical Features

Short Running Title: Elevated LH in Ageing Men


1 University of Manchester, Manchester Academic Health Sciences Centre, Faculty of Medical and Human Sciences, Institute of Human Development, Centre for Endocrinology and Diabetes, Andrology Research Unit, Manchester, United Kingdom
2 Arthritis Research UK Centre for Epidemiology, Division of Musculoskeletal & Dermatological Sciences, Faculty of Biology, Medicine and Health, University of Manchester and NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester NHS Foundation Trust, Manchester, United Kingdom
3 Department of Obstetrics, Gynaecology and Andrology, Albert Szent-György Medical University, Szeged, Hungary

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/cen.13524
This article is protected by copyright. All rights reserved.
4 Department of Medicine, Santiago de Compostela University, Complejo Hospitalario Universitario de Santiago (CHUS); CIBER de Fisiopatología Obesidad y Nutricion (CB06/03), Instituto Salud Carlos III; Santiago de Compostela, Spain

5 Sexual Medicine and Andrology Unit, Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy

6 Department of Translational Medicine, Lund University, Malmö, Sweden

7 Institute of Cardiovascular Research, Royal Holloway University of London (ICR2UL) and Ashford and St Peter's NHS Foundation Trust, Egham, Surrey, United Kingdom

8 Department of Andrology and Reproductive Endocrinology, Medical University of Łódź, Łódź, Poland

9 Department of Human Nutrition, University of Glasgow, Glasgow, United Kingdom

10 Andrology Unit, United Laboratories of Tartu University Clinics, Tartu, Estonia

11 Centre for Clinical and Cognitive Neuroscience, University of Manchester, Manchester, United Kingdom

12 Department of Clinical Biochemistry, University Hospital of South Manchester, Manchester, United Kingdom

13 Department of Andrology and Endocrinology, Katholieke Universiteit Leuven, Leuven, Belgium

14 Manchester Diabetes Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science, Manchester, United Kingdom

15 Cathie Marsh Institute for Social Research. Faculty of Humanities, University of Manchester, Manchester, United Kingdom

16 School of Chemistry, Manchester Institute for Biotechnology, University of Manchester, Manchester, United Kingdom

17 Department of Surgery and Cancer, Institute of Reproductive and Developmental Biology, Imperial College London, Hammersmith Campus, London, United Kingdom and Department of Physiology, Institute of Biomedicine, University of Turku, Finland

This article is protected by copyright. All rights reserved.
Acknowledgements

The European Male Ageing Study is funded by the Commission of the European Communities Fifth Framework Programme “Quality of Life and Management of Living Resources” Grant QLK6-CT-2001-00258 and facilitated by the Manchester Academic Health Sciences Centre and the NIHR Greater Manchester: Clinical Research Network. Additional support was also provided by Arthritis Research United Kingdom and the National Institute for Health Research and the Manchester Academic Health Sciences Centre.

The Principal Investigator of EMAS is Professor Frederick Wu, MD; Andrology Research Unit, University of Manchester, Manchester, United Kingdom. The authors wish to thank the men who participated in the eight countries, the research/nursing staff in the eight centres: C Pott (Manchester), E Wouters (Leuven), M Nilsson (Malmö), M del Mar Fernandez (Santiago de Compostela), M Jedrzejowska (Łódź), H-M Tabo (Tartu), A Heredi (Szeged) for their data collection, and C Moseley (Manchester) for data entry and project co-ordination. Dr. D Vanderschueren is a senior clinical investigator supported by the Clinical Research Fund of the University Hospitals Leuven, Belgium. Robert J.A.H. Eendebak is supported by a Biotechnology and Biological Sciences Research Council – Doctoral Training Partnership (BBSRC-DTP) PhD fellowship and is grateful for support received from the Fundatie van de Vrijvrouwe van Renswoude and Scholten-Cordes scholarship foundations.

Keywords: luteinizing hormone; testosterone; ageing; hypogonadism; physical function

Corresponding author's contact details

Dr Tomás Ahern, MB BCh BAO
Andrology Research Unit, Centre for Endocrinology and Diabetes
Institute of Human Development, Faculty of Medical and Human Sciences
University of Manchester

This article is protected by copyright. All rights reserved.
Abstract

Objective

Elevated LH with normal testosterone (T) suggests compensated dysregulation of the gonadal axis. We describe the natural history, risk factors and clinical parameters associated with the development of high LH (HLH, LH>9.4 U/L) in ageing men with normal T (T≥10.5 nmol/L).

Design, Patients and Measurements

We conducted a 4.3 year prospective observational study of 3,369 community-dwelling European men aged 40-79 years. Participants were classified as: incident (i) HLH (n=101, 5.2%); persistent (p) HLH (n=128, 6.6%); reverted (r) HLH (n=46, 2.4%); or persistent normal LH (pNLH, n=1667, 85.8%). Potential predictors and changes in clinical features associated with iHLH and rHLH were analysed using regression models.

Results

Age >70 years (OR=4.12[2.07–8.20]), diabetes (OR=2.86[1.42–5.77]), chronic pain (OR=2.53[1.34–4.77]), pre-degree education (OR=1.79[1.01–3.20]) and low physical activity (PASE≤78, OR=2.37[1.24–4.50]) predicted development of HLH. Younger age (40-49 years, OR=8.14[1.35-49.13]) and non-smoking (OR=5.39[1.48–19.65]) predicted recovery from HLH. Men with iHLH developed erectile dysfunction, poor health, cardiovascular disease (CVD) and cancer more frequently than pNLH men. In pHLH men, co-morbidities, including
CVD, developed more frequently, and cognitive and physical function deteriorated more, than in pNLH men. Men with HLH developed primary hypogonadism more frequently (OR=15.97[5.85–43.60]) than NLH men. Men with rHLH experienced a small rise in BMI.

Conclusions
Elevation of LH with normal T is predicted by multiple factors, reverts frequently and is not associated with unequivocal evidence of androgen deficiency. High LH is a biomarker for deteriorating health in aged men who tend to develop primary hypogonadism.

Introduction
Ageing is associated with myriad alterations in endocrine functions,¹ some of which may contribute to a decline in health and quality of later life. Elevated LH with normal testosterone (T) is encountered commonly in ageing men² and may present a diagnostic and therapeutic dilemma to the practicing clinician. High LH may signify the onset of dysregulation in the hypothalamic-pituitary-testicular (HPT) axis, whereby compensatory increase in luteinising hormone (LH) is required to mobilise the Leydig cell steroidogenic reserves to maintain normal T production. We have suggested that this may represent a state of ‘compensated’ hypogonadism,² where high LH concentration in the face of normal T (HLH) marks an intermediate stage before transitioning towards overt primary hypogonadism (PHG) when testicular reserve eventually becomes exhausted. The rate of transition (progression and reversal) from normal LH (NLH) to HLH and the factors that influence its development in ageing men are important issues that are yet to be explored in prospective studies. Whether men with HLH experience symptoms, functional deficits or morbidity, without the development of a low T, is unclear. In particular, the proportion of men with HLH who exhibit evidence of androgen deficiency is currently unknown. These uncertainties pose important questions regarding the clinical significance of abnormally increased LH in ageing men.³ The European Male Ageing Study (EMAS)⁴ ⁵ provides an opportunity to help rectify these knowledge gaps through longitudinal observations of unselected men from the general population.

This article is protected by copyright. All rights reserved.
In this study, we aimed to: 1) identify factors predisposing normal LH men to develop high LH and to identify factors, which predict recovery from high LH; 2) determine the clinical features associated with high LH; and 3) assess whether men with high LH are at increased risk of developing PHG.

**Materials and Methods**

*Participants and study design*

The study design and recruitment for EMAS have been described previously. Briefly, an age-stratified sample of 3,369 men aged 40–79 (mean±SD: 60±11) years was recruited from population registers in eight European centres. Participants completed a postal questionnaire and attended a clinic for further assessments. These men were invited to participate in the follow-up assessment a median of 4.3 years later (range: 3.0–5.7 years). During this period, 168 men died and 407 men were lost to follow-up. Ethical approval for the study was obtained in accordance with local requirements in each centre. All participants provided written, informed consent. They completed questionnaires both at baseline and at follow-up about smoking, alcohol consumption, and currently treated medical conditions. Anthropometric measurements, Reuben’s physical performance test (PPT), and psychomotor processing speed estimation (digit symbol substitution test [DSST]) were performed according to standardized methods. Physical, sexual and psychological function was assessed using responses to the Medical Outcome Study (MOS) 36-item Short-Form health survey (SF36), the EMAS Sexual Function Questionnaire and the Beck’s Depression Inventory.

*Hormone measurements*

A single fasting morning (before 1000) blood sample was obtained at baseline and at follow-up. T was measured by liquid chromatography–tandem mass spectrometry (LC–MS/MS), with paired baseline and follow-up samples analysed simultaneously. LH, FSH and SHBG were measured by the E170 platform electrochemiluminescence immunoassay (Roche...
Diagnostics). The Vermeulen formula was used to calculate free (f) T using participant-specific testosterone, SBHG and albumin values. Intra- and inter-assay coefficients of variation (CV) were: T 4.0 and 5.6%; LH 1.9 and 2.7%; FSH 0.9 and 1.9%; and SHBG 1.9 and 3.2%, respectively. The detection limits for the sex hormones were: T (0.17 nmol/L; 0.05 ng/mL), LH (0.10 U/L), FSH (0.10 U/L) and SHBG (0.35 nmol/L). Insulin was assayed using chemiluminescence (CVs: 3.9% and 5%).

Biochemistry/haematology

Standardized measurements were undertaken in laboratories in each centre. Insulin resistance was calculated using the homeostasis model assessment of insulin resistance (HOMA-IR = fasting insulin [U/mL] x fasting glucose [mmol/L]/22.5).^8

Categorisation of participants by LH criteria

Following the criteria described previously,^2 participants were categorised according to LH and T levels: normal LH (NLH, LH≤9.4 U/L and T≥10.5 nmol/L); high LH (HLH, LH>9.4 U/L and T≥10.5 nmol/L). A LH cut-off of 9.4 U/L was chosen because this was the 97.5 centile value for men aged 40 to 44 years in the EMAS population.^9 Participants were further categorised by their change in LH status into one of four groups: incident HLH (iHLH) in which men had a normal LH at baseline and an high LH at follow-up; persistent HLH (pHLH) in which men had HLH at both baseline and follow-up; reverted HLH (rHLH) in which men had HLH at baseline and NLH at follow-up; and pNLH in which men had NLH at both baseline and follow-up.

Statistical analysis

Baseline and follow-up differences between pNLH, iHLH, pHLH and rHLH men in hormone levels, anthropometrics, biochemistry, sexual, physical and psychological function, and health and lifestyle measures were compared between groups using initially the independent-samples t-test or analyses of variance (ANOVA) for continuous variables and \(\chi^2\).
tests for categorical variables. Post-hoc analyses were performed using Tukey-Kramer tests to allow for multiple pairwise comparisons. Longitudinal within-group differences in parameters were compared using the paired t-test for continuous variables and the McNemar test for categorical variables. Multiple regression models, adjusted for centre as a random effect, were used to account for the hierarchical study design (individuals nested within centres). The relationships between LH status and putative predictors were assessed using multilevel binary logistic regression models, where gonadal status was the outcome, with the pNLH or pHLH group being the referent for the analyses of the potential predictors for iHLH or rHLH respectively. Nine factors were included as fixed effects: age (40-49 years, 50-59 years, 60-69 years or ≥70 years), diabetes, BMI (<25 kg/m², 25-29.9 kg/m² or ≥30 kg/m²), smoking status (current, ex or never), alcohol intake (≥5 days per week or <5 days per week), chronic pain, pre-degree education (education obtained to below a university degree level), partner status (living with a partner or not) and physical activity (PASE≤78 or >78). The factors chosen were not collinear – the variance inflation factors were less than 3.33. The relationships between gonadal status and clinical features of high LH were investigated using binary logistic regression models when associations between iHLH, pHLH or rHLH status with sexual, physical and psychological symptoms or medical conditions were assessed, with adjustments for age, comorbidities, BMI, centre, smoking, chronic pain, education and physical activity. Linear regression analysis was used when associations between iHLH, pHLH or rHLH status with functional ratings were assessed, with adjustments for age, comorbidities, BMI, centre, smoking, chronic pain, education and physical activity. Results from linear regression models are presented as β-coefficients (for standardized variables) with 95% confidence intervals (CI) and results from logistic regression models are presented as odds ratios (OR) with 95% CI. All statistical analyses were conducted using STATA SE version 13 (StataCorp, College Station, TX).
Results

Natural history of High LH

Of the 3,369 men recruited into EMAS, 1,942 men made up the analytical sample after exclusion of those with known pituitary, testicular or adrenal disease (n=93), men using a medication known to affect the HPT-axis (n=217), men who had surgical or medical castration (n=2), men who failed to attend for follow-up assessment (n=575), men with missing T (n=77) or LH (n=45) data and men with a testosterone level less than 10.5 nmol/L at baseline or follow-up (n=418, Figure 1). Men with testosterone levels less than 10.5 nmol/L in EMAS have been described separately.\textsuperscript{10,11} Men who died or were lost to follow-up were older, in poorer health, had worse physical and cognitive function and were more likely to smoke (Supplementary Table 1). This attritional group had also lower fT and higher SHBG and LH levels than the analytical sample.

Of 305 (9.6%) men who had HLH at baseline, 36 died, 50 were lost to follow-up, 19 developed medical exclusions (e.g. started taking HPT-axis affecting drugs) and 7 had no follow-up hormone data. In the remaining 193 men with HLH at baseline with available follow-up data, 128 (66.3%) continued to have HLH at follow-up, 46 (23.8%) reverted to NLH, 15 (7.8%) developed PHG and 4 (2.1%) developed SHG. The annual incidence of PHG among men with HLH at baseline was 1.8 (1.1–3.0)%/year.

The analytical sample comprised 1,667 (85.8%) men with pNLH, 101 (5.2%) with iHLH, 128 (6.6%) with pHLH and 46 (2.4%) rHLH men. The incidence (95% confidence interval) of HLH over the follow-up period was 5.7 (4.7 - 6.8)% and the annual incidence rate was 1.3 (1.1 - 1.6)%/year assuming linearity of HLH development. The recovery rate from HLH to NLH was 26.4 (20.5 - 33.5)% and annual recovery rate was 6.8 (5.1–8.9)%/year. The prevalence of HLH at follow-up was 9.5% (n=229).
Characteristics of men who developed high LH

Age, depression (BDI), fasting glucose and PSA were higher, and cognitive function (DSST) and physical activity level (PASE) were lower in iHLH men, at baseline, compared with pNLH men (Table 1). Subjective physical function (SF-36 ratings) and objective physical function (PPT score) were lower in iHLH men at baseline. At follow-up, these earlier differences between the groups persisted, while iHLH men also had lower haemoglobin. The prevalence of poor health and chronic illnesses was higher in the iHLH group than in the pNLH group at both baseline and follow-up (Table 1).

Total T levels were similar in iHLH men and pNLH men at baseline and at follow-up (Table 1). Men with iHLH, compared to pNLH men, had lower fT at baseline (298±94 vs. 327±77 pmol/L, p<0.001) and at follow-up (282±84 vs. 313 ±76 pmol/L, p<0.001) which may have been due to age-related higher SHBG levels at both time-points. As expected by definition, LH levels were higher in iHLH men than in pNLH men (Figure 2).

Characteristics of men who recovered from high LH

Men with rHLH, compared to those with pHLH, were younger, had a lower co-morbidity burden and BMI, and had higher sexual function, cognitive processing speed and physical function at baseline. These baseline differences persisted at follow-up except for BMI (Supplementary table 2).

Men with rHLH had similar T levels at baseline and at follow-up to men with pHLH (Supplementary table 2). Men with rHLH, however, had higher fT levels, compared to men with pHLH, at baseline (333±90 vs 269±74 pmol/L, p<0.001) and at follow-up (312±87 vs 246±74 pmol/L, p<.001). LH levels were lower at baseline and at follow-up in rHLH men compared to pHLH men (Figure 2).
**Predictors of high LH development and recovery**

In men with NLH at baseline, the development of HLH was predicted independently by high age (>70 years, OR 4.12 [2.07–8.20], p<0.001), diabetes (OR 2.86 [1.42–5.77], p=0.003), chronic pain (OR 2.53 [1.34–4.77], p=0.004), education to a below university degree level (OR 1.79 [1.01–3.20], p=0.047) and low physical activity (PASE≤78, OR 2.37 [1.24–4.50], p=0.009, Figure 3).

In men with HLH at baseline, recovery from HLH was predicted independently by younger age (40-49 years, OR 8.14 [1.35–49.13], p=0.022 and 50-59 years, OR 3.38 [1.12–10.19], p=0.030) and by non-smoker status (OR 5.39 [1.48–19.65], p=0.011, Figure 3).

**Symptoms and high LH**

At baseline, NLH men who developed HLH did not report a higher frequency of symptoms compared to pNLH men, apart from sadness. Furthermore, they were less likely to report an inability to bend (Figure 4). At follow-up, men with incident HLH were more likely to experience only a worsening of erectile function, but none of the other 8 symptoms. Men with pHLH and pNLH men did not differ in symptom frequency at baseline - pHLH men were more likely to develop inability to bend, but none of the other symptoms.

The prevalence and incidence of symptoms were similar between rHLH and pHLH men at baseline or follow-up (Figure 4).

**Co-morbidities, Functional Ratings and High LH**

At baseline, men with iHLH were more likely to have diabetes, insulin resistance, lower haemoglobin and lower mood (SF-36 mental) than pNLH men (Table 2). At follow-up, men with iHLH experienced a greater rise in time taken to walk 50 feet, a greater fall in haemoglobin and were more likely to develop poor health, cardiovascular disease and cancer than men with pNLH.
At baseline, men with pHLH were more likely to have diabetes and cancer, lower cognitive processing speed (DSST), higher insulin resistance and lower haemoglobin levels than men with pNLH. During follow-up, men with pHLH, compared to men with pNLH, were more likely to develop co-morbidity, including CVD, while physical function (PPT-rating) and cognitive processing speed worsened more (Table 2).

**Progression from High LH to Primary Hypogonadism (PHG)**

Men with HLH at baseline were more likely to develop PHG in both unadjusted analysis (OR 21.77 [8.76-54.12], p<0.001) and in fully adjusted analysis (OR 15.10 [5.54-41.20], p<0.001) than were NLH men. The annual rate of progression from HLH to PHG was 1.8%/year [1.1–3.0] [total progression rate was 7.8% (4.8-12.4)].

Men who transitioned from HLH to PHG, compared to pHLH men, had lower T (13.5±2.5 vs. 19.1±5.5 nmol/L, p<0.001) and fT levels (189±57 vs. 269±74 pmol/L, p<0.001) at baseline, while LH (20.4±15.5 vs. 14.4±4.8 U/L, p=0.306) and SHBG levels (68.4±50.1 vs. 61.4±21.5 nmol/L, p=0.388) were similar. The transition from HLH to PHG was underlined by noteworthy declines in both T (-4.8±3.5 nmol/L and -34.2±21.2%) and fT (-58±40 pmol/L and -33.3±22.1%), even though T and fT levels were already lower at both baseline and follow-up compared to other groups.

**Discussion**

In this prospective and longitudinal analysis of 3,369 community-dwelling men, we have described, for the first time, the natural history and clinical phenotype of men who develop elevated LH (and normal T), have identified risk factors predisposing to the development of HLH and documented the likelihood of progression to PHG and recovery from HLH.

Men who go onto develop HLH, compared to men who do not, experience a greater fall in haemoglobin and walking speed with increased risks of developing CVD and cancer. These findings, together with the persistently normal mean T of ≥18 nmol/L and a lack of decreased libido and morning erections, suggest that the clinical correlates of iHLH are not typical of hypogonadism, but rather represent those associated with poor or deteriorating health. This
This article is protected by copyright. All rights reserved.
a non-smoker. It is plausible, that, as compared to pHLH men, the younger rHLH men might have a higher reserve of testicular steroidogenic function or Leydig cell population, which allowed them to compensate for potential insults to Leydig cells due to disease. Less likely is the possibility that younger and healthier men had greater LH pulsatility (vide infra) increasing their chance of being classified as HLH at baseline due to blood taking during an LH pulse. The observation that non-smoking is a predictor for the recovery from HLH is in agreement with our baseline cross-sectional findings showing that smoking status is related to HLH.\textsuperscript{2} The higher SHBG levels observed in smokers might explain this finding,\textsuperscript{13} although the exact mechanism, remains unclear. Except for minor changes in BMI, none of the androgen-sensitive endpoints or medical conditions assessed within our study were associated or changed with rHLH. This supports the view that HLH is not a hypogonadal condition although a significant proportion of HLH men will go on to develop PHG within the ensuing 5 years.

The HPT axis is regulated tightly in older as in young men\textsuperscript{14} and elevated LH is highly responsive to age-related deficits in Leydig cell mass\textsuperscript{15} and function.\textsuperscript{16} Impaired testicular response to LH can be caused by exposure to cytokines,\textsuperscript{17,18} arising from chronic low grade inflammation,\textsuperscript{19} which is common in ageing.\textsuperscript{20} Testicular failure with elevated gonadotropins is also associated with chronic diseases of ageing including cancer,\textsuperscript{21} diabetes,\textsuperscript{22} renal and liver failure and COPD.\textsuperscript{23} In addition, elevated LH, independent of testicular failure, has been associated with increased all-cause and cancer-specific mortality.\textsuperscript{24} Elevated LH can be therefore considered a biomarker of poor health and subclinical chronic diseases. Accordingly, iHLH is predicted by the presence of diabetes, and iHLH men are at risk of developing CVD and cancer.

\textit{Strengths and limitations}

This prospective study provided an opportunity to investigate the temporal relationships between the earliest ageing-related changes in HPT-axis function and their clinical correlates. The strengths of the study include the longitudinal follow-up of a large number of
unselected participants from the general population and the breadth of the phenotypic data collected by standardised validated methods between the phases of the study. T was measured by LC–MS/MS with paired baseline and follow-up samples analysed simultaneously. Limitations in EMAS have been described previously.\textsuperscript{4,5} The follow-up period of 4.3 (range: 3.0–5.7) years may be a relatively short time in which to capture more protracted changes in signs and symptoms of hypogonadism. A relatively small number of men developed HLH - this is unavoidable given the relatively low incidence of the condition which has not been previously described. However, the ability to identify significant and consistent associations (albeit with wide confidence intervals) despite the relatively small numbers of cases supports the validity of our findings and conclusions. At both study phases, a single LH and T measurement only was available to categorise gonadal status. This may have introduced errors in classification although the consistency of higher LH between baseline and follow-up and the parallel changes in FSH add confidence to our results. Multiple blood sample collection is impractical in large epidemiological surveys\textsuperscript{25,26} such as ours. Several studies have confirmed that T levels within the same individual do not fluctuate significantly when measured serially over several months.\textsuperscript{27–30} Similarly, the diurnal variation in LH levels is markedly less prominent, if not absent, in older men.\textsuperscript{31} In our analytical sample, the co-efficients of correlation between baseline and follow-up T and LH levels were 0.72 (p<0.001) and 0.80 (p<0.001) respectively. It is unlikely, therefore, that single hormone determination in the present study would have introduced substantial misclassification of gonadal status. The fact that the vast majority of EMAS participants had a normal LH at baseline and at follow-up and the parallel changes in FSH attest to this.

**Conclusions and clinical implications**

Age greater than 70 years, diabetes, chronic pain, pre-degree education and low physical activity predispose men to the development of high LH, which may be reversible in younger men. High LH, (with normal T), can be regarded as a sensitive biomarker of poor health and a risk factor for developing PHG. Incident HLH is not associated with unequivocal evidence
of androgen deficiency. Even if HLH persists for several years, the emergent physical and cognitive impairments are not typical features of hypogonadism, but rather reflect deteriorating health during ageing.

In clinical practice, men with elevated LH and normal T should be followed up for their general as well as endocrine reproductive health, but there is no indication for T replacement therapy unless T falls into the hypogonadal range and more features of androgen deficiency appear (i.e. progression to PHG).

Declaration of Interest

FCWW has acted as a consultant for Bayer-Schering, Eli Lilly and Besins Healthcare and also participated in advisory board meetings and lectured on their behalf. FCWW has received lecture fees from Bayer-Schering and Besins Healthcare. FCWW has received grant support (2010-2014) from Bayer Schering AG and Besins Healthcare. ITH is a consultant and/or has received grants from Ferring Pharmaceuticals and Novartis. All other authors have nothing to disclose.

Funding

The European Male Ageing Study is funded by the Commission of the European Communities Fifth Framework Programme “Quality of Life and Management of Living Resources” Grant QLK6-CT-2001-00258.
References


This article is protected by copyright. All rights reserved.


This article is protected by copyright. All rights reserved.


This article is protected by copyright. All rights reserved.


**Figure Legends**

**Fig. 1.** Flowchart of Participants

pNLH, persistent Normal LH; iHLH, incident High LH; pHLH, persistent High LH; and rHLH, recovery from High LH.

**Fig. 2.** Sex hormone levels and LH status at baseline and follow-up for men with persistent Normal LH (pNLH), incident HLH (iHLH), persistent HLH (pHLH), and recovery from HLH (rHLH)

Baseline and follow-up hormone concentrations are expressed as means (upper limits of bars) and as standard errors of the means (upper limits of the error bars). Data in the groups were compared, and p-values were generated, using analyses of variance (ANOVA) and Tukey-Kramer post-hoc analyses to permit correction for multiple pairwise comparisons.

Solid black bars at follow-up with the letter ‘a’ indicate that follow-up hormone levels in this group differed significantly from baseline hormone levels in the same group when analysed using the paired t-test.

Lines and brackets with stars above bars indicate statistically significant differences between the two groups (p<0.05). The horizontal dotted lines represent values above or below which
are considered abnormal (10.5 nmol/L for total testosterone, 220 pmol/L for calculated free testosterone, and 9.4 U/L for luteinising hormone).

Fig. 3. Potential Risk Factors for development of, and recovery from, High LH
Data are expressed as odds ratio (symbol) ±95% confidence interval (error bars). In the left panels, odds ratios and p-values were determined using single independent variables and binary logistic regression analyses (unadjusted/univariate). In the right panels, odds ratios and p-values were determined using multiple binary logistic regression analysis including all the potential risk factors listed in the same model.
*, p<0.05; **, p<0.01; ***, p<0.001

Fig. 4. Relationships between Symptoms and High LH.
Data are expressed as odds ratios (▲) ±95% confidence intervals (error bars). Odds ratios and p-values were determined using regression analyses. Data from the incident high LH (iHLH) and persistent high LH (pHLH) groups were compared to those from the referent group of persistent normal LH (pNLH). Recovery from high LH (rHLH) data were compared to those of pHLH men. The statistical analysis was performed with adjustment for age, co-morbidity, body mass index, centre, chronic pain, education, smoking, and physical activity. The left panels show the odds ratios for the prevalence of symptoms at baseline. The right panels show the odds ratios for the development/worsening of symptoms.
*, p<0.05; **, p<0.01.
Table 1. Baseline and Follow-Up Characteristics of Men with Persistently Normal LH and those with Incident High LH

<table>
<thead>
<tr>
<th>Parameter</th>
<th>pNLH Baseline</th>
<th>pNLH Follow-Up</th>
<th>iHLH Baseline</th>
<th>iHLH Follow-Up</th>
<th>P*</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>1,667</td>
<td>1,667</td>
<td>101</td>
<td>101</td>
<td></td>
</tr>
<tr>
<td>Age, years</td>
<td>57.2 ±10.1</td>
<td>63.9 ±10.9***</td>
<td>&lt;.001</td>
<td>56.2 ±10.9***</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Pre-degree Education, n (%)</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
</tr>
<tr>
<td>Living with partner, n (%)</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
</tr>
<tr>
<td>Smoking, n (%)</td>
<td>333 (20.2)</td>
<td>23 (22.8)</td>
<td>.052</td>
<td>285 (17.7)***</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Frequent Alcohol, n (%)</td>
<td>415 (25.0)</td>
<td>22 (21.8)</td>
<td>.758</td>
<td>519 (35.9)***</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Chronic widespread pain, n (%)</td>
<td>122 (7.6)</td>
<td>14 (14.4)</td>
<td>.145</td>
<td>---</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Poor health, n (%)</td>
<td>308 (18.6)</td>
<td>31 (31.0)</td>
<td>&lt;.001</td>
<td>353 (21.9)***</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>≥2 illness, n (%)</td>
<td>593 (35.6)</td>
<td>50 (49.5)</td>
<td>&lt;.001</td>
<td>379 (50.2)***</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>≥2Hb, n (%)</td>
<td>216 (16.7)</td>
<td>22 (30.1)</td>
<td>&lt;.001</td>
<td>438 (34.5)***</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Diabetes, n (%)</td>
<td>73 (4.4)</td>
<td>15 (15.0)</td>
<td>&lt;.001</td>
<td>91 (5.6)***</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>CVD, n (%)</td>
<td>466 (28.4)</td>
<td>37 (37.0)</td>
<td>.001</td>
<td>588 (36.7)***</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Cancer, n (%)</td>
<td>59 (3.5)</td>
<td>4 (4.0)</td>
<td>&lt;.001</td>
<td>114 (7.2)***</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Prostate disease, n (%)</td>
<td>135 (8.2)</td>
<td>5 (5.0)</td>
<td>.003</td>
<td>156 (9.7)</td>
<td>0.684</td>
</tr>
<tr>
<td>Overall Sexual Function</td>
<td>22.5 ±6.4</td>
<td>20.2 ±7.2</td>
<td>.002</td>
<td>21.7 ±6.7***</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>SF-36 physical</td>
<td>51.5 ±7.3</td>
<td>49.7 ±8.4</td>
<td>.031</td>
<td>50.9 ±8.0**</td>
<td>0.044</td>
</tr>
<tr>
<td>Beck's Depression Inventory</td>
<td>6.1 ±5.9</td>
<td>8.0 ±6.8</td>
<td>.003</td>
<td>6.0 ±6.4</td>
<td>0.003</td>
</tr>
<tr>
<td>SF-36 mental</td>
<td>52.1 ±8.7</td>
<td>50.3 ±8.4</td>
<td>.016</td>
<td>52.0 ±9.2</td>
<td>0.044</td>
</tr>
<tr>
<td>DSST</td>
<td>29.5 ±8.1</td>
<td>25.3 ±8.6</td>
<td>.001</td>
<td>28.7 ±6.8***</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>PASE score</td>
<td>211.4 ±66.4</td>
<td>183.5 ±95.1</td>
<td>.005</td>
<td>186.4 ±92.7****</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>50-ft walk, sec</td>
<td>13.0 ±2.8</td>
<td>13.5 ±2.8</td>
<td>.040</td>
<td>13.6 ±2.8***</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>27.2 ±3.8</td>
<td>27.2 ±4.1</td>
<td>.035</td>
<td>27.3 ±3.9**</td>
<td>0.822</td>
</tr>
<tr>
<td>FPG, mg/dL</td>
<td>5.4 ±0.9</td>
<td>5.9 ±1.5</td>
<td>.006</td>
<td>5.4 ±1.3*</td>
<td>0.034</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>2.7 ±2.9</td>
<td>3.6 ±7.5</td>
<td>.047</td>
<td>2.7 ±2.1*</td>
<td>0.090</td>
</tr>
<tr>
<td>PSA, ng/ml</td>
<td>1.5 ±2.1</td>
<td>2.2 ±3.6</td>
<td>.003</td>
<td>2.0 ±5.2***</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Hb, g/L</td>
<td>150.8 ±10.4</td>
<td>148.5 ±11.2</td>
<td>.053</td>
<td>150.7 ±10.8</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Total T, nmol/L</td>
<td>18.4 ±5.4</td>
<td>18.0 ±5.1</td>
<td>.611</td>
<td>18.1 ±5.4**</td>
<td>0.018</td>
</tr>
<tr>
<td>Free T, pmol/L</td>
<td>326.7 ±7.7</td>
<td>298.4 ±93.7</td>
<td>&lt;.001</td>
<td>312.6 ±76.0**</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>SHBG, nmol/L</td>
<td>42.9 ±17.3</td>
<td>48.3 ±17.0</td>
<td>&lt;.001</td>
<td>45.4 ±18.7***</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>LH, U/L</td>
<td>5.0 ±1.7</td>
<td>7.4 ±1.4</td>
<td>&lt;.001</td>
<td>5.0 ±1.8</td>
<td>0.001</td>
</tr>
<tr>
<td>FSH, U/L</td>
<td>6.1 ±3.4</td>
<td>11.2 ±6.2</td>
<td>&lt;.001</td>
<td>6.2 ±3.5</td>
<td>0.001</td>
</tr>
</tbody>
</table>

Data are expressed as mean ±standard deviation for continuous variables or as number (percentage) for binary categorical variables. Abbreviations: NLH, Normal Luteinising Hormone; HLH, High Luteinising Hormone; CVD, CardioVascular Disease; SF-36, Short-Form 36 Questionnaire; DSST, Digital Symbol Substitution Test; PASE, Physical Activity Scale for the Elderly; PPT, Physical Performance Test; BMI, Body Mass Index; FPG, Fasting Plasma Glucose concentration; HOMA-IR, HOMeostatic Model of Insulin Resistance; PSA, Prostate Specific Antigen concentration; Hb, Haemoglobin; T, serum Testosterone concentration; SHBG, Sex Hormone Binding Globulin concentration; LH, Luteinising Hormone concentration; FSH, Follicular Stimulating Hormone concentration.

a. P values were calculated using baseline parameters and either the independent-samples t-test for continuous variables or chi-squared analyses for categorical variables.
b. P values were calculated using follow-up parameters and either the independent-samples t-test for continuous variables or chi-squared analyses for categorical variables.
c. Educated to less than a degree level

* ** *** Data differ significantly (p<0.05, p<0.01 and p<0.001 respectively) from baseline values within the same group when analysed using paired t-tests (for continuous variables) or the McNemar test (for categorical variables).

This article is protected by copyright. All rights reserved.
**Table 2. Co-morbidities, Functional Ratings and Elevated Luteinising Hormone**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Incident HLH (n=101)</th>
<th>Persistent HLH (n=128)</th>
<th>Recovery from HLH (n=46)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td>Change&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Baseline</td>
</tr>
<tr>
<td>Poor health, n (%)</td>
<td>1.29 (0.76, 2.18)</td>
<td>1.98 (1.01, 3.90)*</td>
<td>1.39 (0.86, 2.22)</td>
</tr>
<tr>
<td>≥1 illness, n (%)</td>
<td>1.10 (0.68, 1.78)</td>
<td>1.75 (0.92, 3.31)</td>
<td>1.76 (1.12, 2.76)*</td>
</tr>
<tr>
<td>≥2 illnesses, n (%)</td>
<td>0.99 (0.52, 1.86)</td>
<td>1.85 (0.84, 4.06)</td>
<td>1.85 (1.05, 3.26)*</td>
</tr>
<tr>
<td>Diabetes, n (%)</td>
<td>2.62 (1.34, 5.14)**</td>
<td>0.35 (0.05, 2.73)</td>
<td>2.13 (1.12, 4.08)*</td>
</tr>
<tr>
<td>CVD, n (%)</td>
<td>0.89 (0.54, 1.46)</td>
<td>2.09 (1.12, 3.90)*</td>
<td>1.37 (0.88, 2.12)</td>
</tr>
<tr>
<td>Cancer, n (%)</td>
<td>0.67 (0.20, 2.25)</td>
<td>2.77 (1.29, 5.97)*</td>
<td>2.06 (1.05, 4.05)*</td>
</tr>
<tr>
<td>Prostate disease, n (%)</td>
<td>0.27 (0.09, 0.77)*</td>
<td>1.18 (0.53, 2.66)</td>
<td>1.21 (0.70, 2.09)</td>
</tr>
<tr>
<td>Overall Sexual Function</td>
<td>-0.03 (-0.08, 0.02)</td>
<td>-0.02 (-0.08, 0.04)</td>
<td>-0.02 (-0.07, 0.02)</td>
</tr>
<tr>
<td>SF-36 physical Inventory</td>
<td>0.01 (-0.03, 0.06)</td>
<td>-0.03 (-0.08, 0.02)</td>
<td>-0.00 (-0.05, 0.04)</td>
</tr>
<tr>
<td>Beck’s Depression</td>
<td>0.03 (-0.01, 0.08)</td>
<td>0.03 (-0.02, 0.09)</td>
<td>0.04 (-0.01, 0.09)</td>
</tr>
<tr>
<td>SF-36 mental</td>
<td>-0.05 (-0.10, -0.00)*</td>
<td>-0.00 (-0.05, 0.05)</td>
<td>-0.01 (-0.06, 0.04)</td>
</tr>
<tr>
<td>DSST</td>
<td>-0.03 (-0.07, 0.01)</td>
<td>-0.02 (-0.07, 0.03)</td>
<td>-0.07 (-0.11, -0.02)**</td>
</tr>
<tr>
<td>PASE score</td>
<td>-0.03 (-0.08, 0.01)</td>
<td>0.02 (-0.03, 0.08)</td>
<td>-0.04 (-0.09, 0.01)</td>
</tr>
<tr>
<td>50-ft walk, seconds</td>
<td>-0.01 (-0.06, 0.03)</td>
<td>0.05 (0.001, 0.10)**</td>
<td>-0.00 (-0.05, 0.04)</td>
</tr>
<tr>
<td>PPT rating</td>
<td>0.01 (-0.04, 0.05)</td>
<td>-0.01 (-0.06, 0.04)</td>
<td>0.00 (-0.04, 0.05)</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>-0.01 (-0.05, 0.04)</td>
<td>-0.01 (-0.06, 0.04)</td>
<td>-0.04 (-0.09, 0.01)</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>0.07 (0.02, 0.11)**</td>
<td>-0.02 (-0.07, 0.04)</td>
<td>0.09 (0.04, 0.14)**</td>
</tr>
<tr>
<td>Hb, g/L</td>
<td>-0.05 (-0.10, -0.00)*</td>
<td>-0.06 (-0.11, -0.01)*</td>
<td>-0.10 (-0.15, -0.04)**</td>
</tr>
</tbody>
</table>

Data are expressed as odds ratio (95% confidence interval) for binary categorical variables or as regression coefficient (95% confidence interval) for continuous variables. Data from men with incident or persistent HLH were compared to those from men with persistently normal LH levels. Data from men with recovery from HLH were compared to those from men with persistent HLH. All relationships are adjusted for co-morbidity, body mass index, centre, chronic pain, education, smoking, and physical activity.

Abbreviations: HLH, High Luteinising Hormone; CVD, CardioVascular Disease; SF-36, Short-Form 36 Questionnaire; DSST, Digital Symbol Substitution Test; PASE, Physical Activity Scale for the Elderly; PPT, Physical Performance Test; BMI, Body Mass Index; HOMA-IR, Homeostatic Model of Insulin Resistance; Hb, Haemoglobin.

* p<0.05; ** p<0.01; *** p<0.001
3,369 men recruited at baseline

179 excluded at baseline due to known pituitary, testicular or adrenal disease or current use of medication known to affect the hypothalamic-pituitary-gonadal axis

3,190 men after baseline exclusions

168 men died
407 men lost to follow-up

2,615 men attended for follow-up assessment

132 excluded at follow-up assessment due to development of pituitary, testicular or adrenal disease or current use of medication known to affect the hypothalamic-pituitary-gonadal axis

2,483 men after follow-up exclusions

123 excluded due to missing testosterone or LH data at baseline or at follow-up
418 excluded due to hypogonadism (T<10.5 nmol/L) at baseline or at follow-up

1,942 men in the analytical sample

1,667 pNLH
101 iHLH
128 pHLH
46 rHLH
a) Incident High Luteinising Hormone - predictors

- Age 50-59 years
- Age 60-69 years
- Age >70 years
- Diabetes
- Overweight
- Obese
- Chronic pain
- Current Smoking
- Frequent Alcohol (≥5 d/week)
- Pre-degree Education
- Living with Partner
- PASE ≤78

b) Recovery from High Luteinising Hormone - predictors

- Age 60-69 years
- Age 50-59 years
- Age 40-49 years
- No diabetes
- Overweight
- Lean body weight
- Chronic pain
- Non-smoking
- Non-frequent Alcohol intake (<5 d/week)
- Pre-degree Education
- Living with Partner
- PASE > 78